Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Cross-bridge Cycle01:26

Cross-bridge Cycle

As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
Esophageal Achalasia01:27

Esophageal Achalasia

Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026
Same author

Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance.

Journal of autoimmunity·2026
Same author

Neurologic immune-related adverse events from immune checkpoint inhibitors: recent advances and future prospectives.

Immunological medicine·2026
Same author

Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter study.

Internal medicine (Tokyo, Japan)·2026
Same author

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Nature communications·2026
Same author

Anti-Signal Recognition Particle Antibody-Positive Immune-Mediated Necrotizing Myopathy Diagnosed by Re-Evaluation 40 Years After Symptom Onset.

Neuropathology : official journal of the Japanese Society of Neuropathology·2025

Related Experiment Videos

[Lambert-Eaton myasthenic syndrome (LEMS)].

Shigeaki Suzuki1

  • 1Department of Neurology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|April 28, 2010
PubMed
Summary

Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular disorder affecting acetylcholine release. Autoantibodies against P/Q-type VGCCs are common, and LEMS is linked to small cell lung cancer.

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Background:

  • Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder impacting neuromuscular transmission.
  • It is characterized by autoantibodies primarily targeting P/Q-type voltage-gated calcium channels (VGCCs), impairing acetylcholine release.
  • LEMS exhibits a strong association with small cell lung cancer (SCLC), occurring in 50-60% of patients.

Purpose of the Study:

  • To provide a comprehensive overview of Lambert-Eaton myasthenic syndrome.
  • To discuss the pathophysiology, clinical manifestations, diagnostic findings, and treatment strategies for LEMS.
  • To highlight the association between LEMS and small cell lung cancer.

Main Methods:

  • Review of existing literature on LEMS pathophysiology, clinical presentation, and treatment.

Related Experiment Videos

  • Analysis of diagnostic criteria, including autoantibody testing and electrophysiological findings.
  • Summarization of current therapeutic approaches, encompassing tumor treatment, symptomatic management, and immunotherapy.

    • Main Results:

    • LEMS is an autoimmune neuromuscular junction disorder caused by autoantibodies against presynaptic VGCCs.
    • Clinical features include proximal muscle weakness, reduced reflexes, ptosis, ataxia, and autonomic dysfunction.
    • Electrophysiological studies reveal low-amplitude compound muscle action potentials with a high-rate stimulation increment.
    • Anti-VGCC antibodies are present in 85% of LEMS patients; other antibodies like anti-synaptotagmin and anti-SOX1 are also found.
    • LEMS is strongly linked to SCLC, and anti-VGCC antibodies in SCLC patients may indicate a favorable prognosis.

    Conclusions:

    • LEMS is a complex disorder with both autoimmune and paraneoplastic components.
    • Early diagnosis and appropriate management, including tumor treatment and immunotherapy, are crucial for patient outcomes.
    • Understanding the immunological basis and cancer associations of LEMS is vital for effective patient care.